Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels
- 17 November 2014
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 111 (48), E5187-E5195
- https://doi.org/10.1073/pnas.1413828111
Abstract
We identified previously in vitro LRP4 (low-density lipoprotein receptor-related protein 4) as a facilitator of the WNT (Wingless-type) antagonist sclerostin and found mutations disrupting this function to be associated with high bone mass in humans similar to patients lacking sclerostin. To further delineate the role of LRP4 in bone in vivo, we generated mice lacking Lrp4 in osteoblasts/osteocytes or osteocytes only. Lrp4 deficiency promoted progressive cancellous and cortical bone gain in both mutants, although more pronouncedly in mice deficient in osteoblast/osteocyte Lrp4, consistent with our observation in human bone that LRP4 is most strongly expressed by osteoblasts and early osteocytes. Bone gain was related primarily to increased bone formation. Interestingly, Lrp4 deficiency in bone dramatically elevated serum sclerostin levels whereas bone expression of Sost encoding for sclerostin was unaltered, indicating that osteoblastic Lrp4 retains sclerostin within bone. Moreover, we generated anti-LRP4 antibodies selectively blocking sclerostin facilitator function while leaving unperturbed LRP4–agrin interaction, which is essential for neuromuscular junction function. These antibodies increased bone formation and thus cancellous and cortical bone mass in skeletally mature rodents. Together, we demonstrate a pivotal role of LRP4 in bone homeostasis by retaining and facilitating sclerostin action locally and provide a novel avenue to bone anabolic therapy by antagonizing LRP4 sclerostin facilitator function.Keywords
This publication has 60 references indexed in Scilit:
- Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapsesNature, 2012
- Bone Overgrowth-associated Mutations in the LRP4 Gene Impair Sclerostin Facilitator FunctionOnline Journal of Public Health Informatics, 2011
- Lrp4: A novel modulator of extracellular signaling in craniofacial organogenesisAmerican Journal of Medical Genetics Part A, 2010
- Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodiesProceedings of the National Academy of Sciences of the United States of America, 2010
- LRP4 Mutations Alter Wnt/β-Catenin Signaling and Cause Limb and Kidney Malformations in Cenani-Lenz SyndromeAmerican Journal of Human Genetics, 2010
- Wnt10b deficiency results in age-dependent loss of bone mass and progressive reduction of mesenchymal progenitor cellsJournal of Bone and Mineral Research, 2010
- Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studiesNature Genetics, 2009
- LRP4 Serves as a Coreceptor of AgrinNeuron, 2008
- Multiple Genetic Loci for Bone Mineral Density and FracturesThe New England Journal of Medicine, 2008
- The Human Combinatorial Antibody Library HuCAL GOLD Combines Diversification of All Six CDRs According to the Natural Immune System with a Novel Display Method for Efficient Selection of High-Affinity AntibodiesJournal of Molecular Biology, 2008